[et_pb_section fb_built=”1″ _builder_version=”4.5.3″ custom_margin=”||0px||false|false” custom_padding=”||0px||false|false”][et_pb_row _builder_version=”3.25″ background_size=”initial” background_position=”top_left” background_repeat=”repeat”][et_pb_column type=”4_4″ _builder_version=”3.25″ custom_padding=”|||” custom_padding__hover=”|||”][et_pb_text _builder_version=”4.5.3″ background_size=”initial” background_position=”top_left” background_repeat=”repeat”] For the past four years, the Milner Therapeutics Institute has been incubating in the Gurdon Institute – home to the research lab of our Director Tony Kouzarides. This provided essential support as the Milner team was growing and …
Launch of the Milner Therapeutics Institute
This month, we celebrated the launch of the Milner Therapeutics Institute in the Jeffrey Cheah Biomedical Centre. Key academics and consortium members gathered in our brand new auditorium. Our Director, Tony Kouzarides, gave the vision of the Milner Therapeutics Institute and lead scientists presented work from the different units within our new building, namely the …
AstraZeneca-Cancer Research UK Functional Genomics Centre launch
We are excited to be celebrating the launch of the AstraZeneca-Cancer Research UK Functional Genomics Centre today. Based in the Milner Therapeutics Institute, this collaborative team will be utilising CRISPR technologies to better understand cancer biology, creating biological models that aim to more accurately reflect human disease. Alongside the support and expertise it will provide …
Welcome to Cambridge Centre for Proteomics
A warm welcome to the team of Kathryn Lilley at the Cambridge Centre for Proteomics (CCP), who are moving into the Milner Therapeutics Institute this week! The group have just returned from the Human Proteome Organisation (HUPO) meeting in Australia, where Kathryn Lilley presented a plenary talk and two group members received prizes. Dr Eneko …
First pre-competitive project initiated
A key goal of the Milner Therapeutics Consortium is to enable collaborations between Cambridge academics and our Consortium companies using forward-thinking pre-competitive models. We can now announce that the first such project has been established with Ludovic Vallier at the Wellcome MRC Cambridge Stem Cell Institute, focused on the identification of new therapeutics for liver …
New University Enterprise Zone announced
The Milner Therapeutics Institute will form part of a University Enterprise Zone, created through a new government initiative announced today by Universities Minister Chris Skidmore. Research England, part of UK Research and Innovation, today announced 20 new University Enterprise Zones (UEZs) aimed at helping universities stimulate growth in their local economies, providing vital support for …
Welcome to Pathania group
We are delighted to welcome the group of Manav Pathania (Dept Oncology), who moved into the Milner Institute this month. The Pathania group have a central focus on developing new mouse models for children’s brain tumours, to better understand the diverse genetic basis of different brain tumour types. By applying CRISPR technology to test genetic …
Renewal of Milner Therapeutics Consortium
We are delighted to announce that the Milner Therapeutics Consortium has been renewed until 2024. The Consortium includes 7 pharma companies (Astex, AstraZeneca, Ferring, GlaxoSmithKline, J & J Innovation, Pfizer, Shionogi) who are committed to collaboration and research investment in Cambridge academic institutes. “The renewal of this Consortium is a fantastic opportunity for the Milner …
New Opportunity for an Administrator and Finance Coordinator
Administrator and Finance Coordinator We are looking to appoint a new and key role in our brand new purpose built facilities in the Jeffrey Cheah Biomedical Centre on the Cambridge Biomedical Campus. This is an exciting and challenging opportunity for a motivated individual to shape and set up critical processes in the Institute. The role …
Cambridge Biotech Week
The Milner Therapeutics Symposium 2019 is part of Cambridge Biotech Week (25-28th June), a festival of events focused on accelerating scientific ideas and facilitating investment and growth for both early and mature companies on the cutting-edge of healthcare and life sciences. Read more